What should I do if I become resistant to sotolaxib?

Sotoracib (AMG510)is the first targeted drug targeting the KRAS G12C mutation. It is used to treat patients with KRAS who have received at least one systemic treatment in the past. Patients with G12Cmutated locally advanced or metastatic non-small cell lung cancer (NSCLC). What should I do if I become resistant to sotolaxib?

First, it can be switched to other targeted drugs. Adagrasibu is the second targeted drug targeting the KRAS G12C mutation. This drug was approved for marketing in the United States on December 12, 2022. According to relevant trials, adagrasibu is superior to sotorasib. However, the cost is relatively high. Each box currently sells for about 160,000 to 70,000 yuan. Patients can choose drugs according to their own financial situation; the second option is immunotherapy. Immunotherapy can improve the patient's immune system's ability to attack cancer cells, thus inhibiting tumor growth. Patients can choose immunotherapy according to the doctor's advice. The third chemotherapy. Chemotherapy is a common method of treating tumors. Chemotherapy is a drug treatment that uses powerful chemicals to kill rapidly growing cells in the body. Chemotherapy is most commonly used to treat cancer because cancer cells grow and multiply much faster than most cells in the body. Chemotherapy drugs can be used alone or in combination to treat various cancers. Patients can choose treatment options based on their doctor’s recommendations. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.